Data From QIN PROSTATE

This collection contains multiparametric MRI images collected for the purposes of detection and/or staging of prostate cancer. The MRI parameters include T1- and T2-weighted sequences as well as Diffusion Weighted and Dynamic Contrast-Enhanced MRI. The images were obtained using endorectal and phased array surface coils at 3.0T (GE Signa HDx 15.0) The value of this collection is to provide clinical image data for the development and evaluation of quantitative methods for prostate cancer characterization using multiparametric MRI. Data was provided by Brigham and Women's Hospital, PI Dr. Fiona Fennessy. MR imaging exam was performed on a GE Signa HDx 3.0 T magnet (GE Healthcare, Waukesha, WI) using a combination of 8-channel abdominal array and endorectal coil (Medrad, Pittsburgh, PA). The MR sequences included T1- and T2-weighted imaging, diffusion weighted (DW) imaging, and DCE MRI. T1-weighted imaging was performed with a spoiled gradient recalled echo (SPGR) sequence with TR/TE/α = 385 ms/6.2 ms/65° over a (16 cm)2 field of view (FOV). T2-weighted imaging was performed with a FRFSE (Fast Recovery Fast Spin Echo) sequence with TR/TE = 3500/102 ms, FOV = (16 cm)2. A DW echo planar imaging sequence with trace diffusion sensitization and b-values of 0 and 500 s/mm2, and TR/TE = 2500/65 ms provided data for an Apparent Diffusion Coefficient (ADC) map. Finally, DCE MRI utilized a 3D SPGR sequence with TR/TE/α = 3.6 ms/1.3 ms/15°, FOV = (26 cm)2, with full gland coverage and reconstructed image voxel size of 1×1×6 mm (interpolated to 256×256 matrix). DCE MRI frames were acquired at approximately 5 s intervals (the number of frames varied between 12 and 16 slices resulting in the time resolution between 4.4 and 5.3 seconds) to achieve a clinically appropriate compromise between spatial and temporal resolutions. Gadopentetate dimeglumine (Magnevist, Berlex Laboratories, Wayne, New Jersey) was injected intravenously using a syringe pump (0.15 mmol/kg) at the rate of 3 ml/s followed by 20 ml saline flush at the same rate. The protocol included ~ 5 baseline scans prior to contrast injection for estimation of baseline tissue properties.

本数据集收录了用于前列腺癌检测及/或分期的多参数磁共振成像（multiparametric MRI）图像。所用磁共振成像参数包含T1加权、T2加权序列，以及弥散加权成像（Diffusion Weighted Imaging，DWI）与动态对比增强磁共振成像（Dynamic Contrast-Enhanced MRI，DCE-MRI）。图像采用3.0T GE Signa HDx 15.0扫描仪，通过直肠内相控阵表面线圈采集。

本数据集的核心价值在于为基于多参数MRI的前列腺癌定量表征方法的开发与评估提供临床影像数据。该数据集由布莱根妇女医院（Brigham and Women's Hospital）提供，项目负责人为菲奥娜·芬尼西（Fiona Fennessy）博士。

本次磁共振成像检查实际在GE Signa HDx 3.0T磁体（GE医疗，沃基肖，威斯康星州）上完成，采用8通道腹部相控阵线圈与直肠内线圈（Medrad，匹兹堡，宾夕法尼亚州）联合采集。所用磁共振序列包括T1加权成像、T2加权成像、弥散加权成像及DCE-MRI：
T1加权成像采用扰相梯度回波（spoiled gradient recalled echo，SPGR）序列，参数设置为TR/TE/α=385ms/6.2ms/65°，视野（field of view，FOV）为(16cm)²；
T2加权成像采用快速恢复快速自旋回波（Fast Recovery Fast Spin Echo，FRFSE）序列，TR/TE=3500/102ms，FOV=(16cm)²；
弥散加权成像采用回波平面成像（echo planar imaging，EPI）序列，实施弥散敏感轨迹成像，b值为0和500 s/mm²，TR/TE=2500/65ms，可生成表观弥散系数（Apparent Diffusion Coefficient，ADC）图；
DCE-MRI采用3D SPGR序列，TR/TE/α=3.6ms/1.3ms/15°，FOV=(26cm)²，可完整覆盖前列腺腺体，重建后图像体素尺寸为1×1×6mm（插值至256×256矩阵）。DCE-MRI图像以约5秒的间隔采集帧图像，每层面的采集帧数为12至16帧，最终时间分辨率为4.4至5.3秒，在空间分辨率与时间分辨率之间取得了临床适用的平衡。

静脉注射钆喷酸葡胺（Gadopentetate dimeglumine，商品名Magnevist，Berlex实验室，韦恩，新泽西州）作为对比剂，采用注射泵给药，剂量为0.15mmol/kg，注射速率为3ml/s，随后以相同速率推注20ml生理盐水冲管。本扫描方案在对比剂注射前采集了约5次基线扫描，用于估算基线组织特性。